Otsuka Holdings reports strong Q3 results, revises full-year forecast upward

For the nine months ended September 30, 2025, Otsuka Holdings reported consolidated revenue of 1,818,743 million yen, a 5.1% increase year-over-year. Operating profit surged by 56.1% to 407,421 million yen, while profit for the period attributable to owners of the parent rose 55.3% to 297,658 million yen. Basic earnings per share were 560.81 yen, up significantly from 353.33 yen in the prior year. This growth was primarily fueled by strong sales in the pharmaceutical and nutraceutical segments, despite increased research and development expenses.

The company updated its full-year consolidated earnings forecast for 2025, anticipating revenue of 2,420,000 million yen, a 1.7% increase from the previous forecast. Operating profit is projected to be 452,000 million yen, up 0.4%, and profit for the period attributable to owners of the parent is expected to be 330,000 million yen. This revision is attributed to favorable exchange rates and strong performance of key pharmaceutical products.

Cash and cash equivalents increased by 65,971 million yen to 492,145 million yen at the end of the third quarter. The company’s total assets grew by 220,287 million yen to 3,959,538 million yen, while total equity attributable to owners of the parent increased to 2,859,120 million yen. Dividends for the fiscal year are projected to be 140.00 yen per share, with an interim dividend of 70.00 yen already paid.